Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma

Laboratory Investigation

Volumn 86, Issue 11, 2006, Pages 1149-1160

  Tátrai, Péter ^a   Dudás, József ^b   Batmunkh, Enkhjargal ^a   Máthé, Miklós ^a   Zalatnai, Attila ^a   Schaff, Zsuzsa ^a   Ramadori, Giuliano ^b   Kovalszky, Ilona ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Agrin; Basement membrane; Cirrhosis; Heparan sulfate proteoglycan; Hepatocellular carcinoma; Neoangiogenesis

Indexed keywords

AGRIN; CD51 ANTIGEN; GROWTH FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BILE DUCT; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MESENCHYME CELL; MICROVASCULATURE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TUMOR VASCULARIZATION; VASCULAR SMOOTH MUSCLE;

AGRIN; ANIMALS; BASEMENT MEMBRANE; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KUPFFER CELLS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICROCIRCULATION; MUSCLE CELLS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 33750367402     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700475     Document Type: Article

References (36)

1. Gallai M, Kovalszky I, Knittel T, et al. Expression of extracellular matrix proteoglycans perlecan and decorin in carbon-tetrachloride-injured rat liver and in isolated liver cells. Am J Pathol 1996;148:1463-1471.
2. Kovalszky I, Nagy P, Szende B, et al. Experimental and human liver fibrogenesis. Scand J Gastroenterol Suppl 1998;228:51-55.
3. Dudas J, Kovalszky I, Gallai M, et al. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am J Clin Pathol 2001;115:725-735.
4. Hogemann B, Edel G, Schwarz K, et al. Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract 1997;193:747-751.
5. Kovalszky I, Schaff Z, Jeney A. Potential markers (enzymes, proteoglycans) for human liver tumors. Acta Biomed Ateneo Parmense 1993;64:157-163.
6. Rescan PY, Loreal O, Hassell JR, et al. Distribution and origin of the basement membrane component perlecan in rat liver and primary hepatocyte culture. Am J Pathol 1993;142:199-208.
7. Aviezer D, Hecht D, Safran M, et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994;79:1005-1013.
8. Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003;51:1393-1410.
9. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999;274:18843-18846.
10. Bezakova G, Ruegg MA. New insights into the roles of agrin. Nature Rev Mol Cell Biol 2003;4:295-309.
11. Groffen AJ, Veerkamp JH, Monnens LA, et al. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol Dial Transplant 1999;14: 2119-2129.
12. Gesemann M, Brancaccio A, Schumacher B, et al. Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue. J Biol Chem 1998;273:600-605.
13. Martin PT, Sanes JR. Integrins mediate adhesion to agrin and modulate agrin signaling. Development 1997;124:3909-3917.
14. Burgess RW, Dickman DK, Nunez L, et al. Mapping sites responsible for interactions of agrin with neurons. J Neurochem 2002;83:271-284.
15. McMahan UJ. The agrin hypothesis. Cold Spring Harb Symp Quant Biol 1990;55:407-418.
16. Cole GJ, Halfter W. Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 1996;3:359-371.
17. Kroger S, Schroder JE. Agrin in the developing CNS: new roles for a synapse organizer. News Physiol Sci 2002;17:207-212.
18. Barber AJ, Lieth E. Agrin accumulates in the brain microvascular basal lamina during development of the blood-brain barrier. Dev Dyn 1997;208:62-74.
19. Khan AA, Bose C, Yam LS, et al. Physiological regulation of the immunological synapse by agrin. Science 2001;292:1681-1686.
20. Groffen AJ, Ruegg MA, Dijkman H, et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histochem Cytochem 1998;46:19-27.
21. Knittel T, Kobold D, Saile B, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999;117:1205-1221.
22. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-517.
23. Zalatnai A, Lapis K. Simultaneous induction of liver cirrhosis and hepatocellular carcinomas in F-344 rats: establishment of a short hepatocarcinogenesis model. Exp Toxicol Pathol 1994;46:215-222.
24. Neubauer K, Knittel T, Aurisch S, et al. Glial fibrillary acidic protein-a cell type specific marker for Ito cells in vivo and in vitro. J Hepatol 1996;24:719-730.
25. Saile B, Matthes N, Neubauer K, et al. Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2002;283: G435-G444.
26. Lyon M, Gallagher JT. Purification and partial characterisation of the major cell-associated heparan sulphate proteoglycan of rat liver. Biochem J 1991; 273:415-422.
27. Kemeny E, Fillit HM, Damle S, et al. Monoclonal antibodies to heparan sulfate proteoglycan: development and application to the study of normal tissue and pathologic human kidney biopsies. Connect Tissue Res 1988;18:9-25.
28. Stanley MJ, Stanley MW, Sanderson RD, et al. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999;112:377-383.
29. Bayer-Garner IB, Dilday B, Sanderson RD, et al. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma. Am J Dermatopathol 2000;22:119-122.
30. Wiksten JP, Lundin J, Nordling S, et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001; 95:1-6.
31. Ito Y, Yoshida H, Nakano K, et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003;43:157-164.
32. Mukunyadzi P, Liu K, Hanna EY, et al. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 2003; 16:796-801.
33. Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-297.
34. Tsen G, Napier A, Halfter W, et al. Identification of a novel alternatively spliced agrin mRNA that is preferentially expressed in non-neuronal cells. J Biol Chem 1995;270:15934-15937.
35. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-1230.
36. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-335.